Serum lactate dehydrogenase isoenzyme 1 as a prognostic predictor for metastatic testicular germ cell tumours – reply

Por Shamash, J
Publicado em 2000

Comment on ‘Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'

Por Shamash, J, Sarker, S-J
Publicado em 2014

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

Por Powles, T, Shamash, J, Berney, D, Oliver, R T D
Publicado em 2003

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer

Por Shamash, J, Davies, A, Ansell, W, Mcfaul, S, Wilson, P, Oliver, T, Powles, T
Publicado em 2008

DNA topoisomerase I and II expression in drug resistantgerm cell tumours

Por Berney, D M, Shamash, J, Gaffney, J, Jordan, S, Oliver, R T D
Publicado em 2002

Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers – a new active regimen

Por Slater, S, Shamash, J, Wilson, P, Gallagher, C J, Slevin, M L
Publicado em 2002

In vitro testing of calcium channel blockers and cytotoxic chemotherapy in B-cell low-grade non-Hodgkin's lymphoma.

Por Shamash, J., Salam, A. H., Davies, D. C., Williams, A., Joel, S., Lister, T. A.
Publicado em 1998

Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding

Por Shamash, J, Dancey, G, Barlow, C, Wilson, P, Ansell, W, Oliver, R T D
Publicado em 2005

Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided?

Por Berney, D M, Shamash, J, Hendry, W F, Arora, A, Jordan, S, Oliver, R T
Publicado em 2001

IPM chemotherapy in cytokine refractory renal cell cancer

Por Shamash, J, Steele, J P, Wilson, P, Nystrom, M, Ansell, W, Oliver, R T D
Publicado em 2003

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours

Por Shamash, J, Powles, T, Ansell, W, Stebbing, J, Mutsvangwa, K, Wilson, P, Asterling, S, Liu, S, Wyatt, P, Joel, S P, Oliver, R T D
Publicado em 2007

Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy

Por Shamash, J, Oliver, R T D, Gallagher, C J, Newland, A C, Lister, T A, Kelsey, S, Gupta, R K, O'Doherty, C A
Publicado em 2000

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours

Por Shamash, J, Powles, T, Ansell, W, Berney, D, Stebbing, J, Mutsvangwa, K, Wilson, P, Asterling, S, Liu, S, Wyatt, P, Joel, S P, Oliver, R T D
Publicado em 2007

A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol

Por Shamash, J, Powles, T, Sarker, S J, Protheroe, A, Mithal, N, Mills, R, Beard, R, Wilson, P, Tranter, N, O'Brien, N, McFaul, S, Oliver, T
Publicado em 2011

Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour

Por Rimmer, Y, Chester, J, Joffe, J, Stark, D, Shamash, J, Powles, T, White, J, Wason, J, Parashar, D, Armstrong, G, Mazhar, D, Williams, M V
Publicado em 2011

Outcome of patients with HIV-related germ cell tumours: a case–control study

Por Powles, T, Bower, M, Shamash, J, Stebbing, J, Ong, J, Daugaard, G, De Ruiter, A, Johnson, M, Fisher, M, Anderson, J, Nelson, M, Gazzard, B, Oliver, T
Publicado em 2004

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

Por Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.
Publicado em 2011